Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray

Breast cancer remains the second leading cause of cancer-related death in women despite stratification based on standard hormonal receptor (HR) and HER2 testing. Additional prognostic markers are needed to improve breast cancer treatment. Chromothripsis, a catastrophic genome rearrangement, has been described recently in various cancer genomes and affects cancer progression and prognosis. However, little is known about chromothripsis in breast cancer. To identify novel prognostic biomarkers in breast cancer, we used molecular inversion probe (MIP) microarray to explore genome-wide copy number aberrations (CNA) and breast cancer-related gene alterations in DNA extracted from formalin-fixed paraffin-embedded tissue. We examined 42 primary breast cancers with known HR and HER2 status assessed via immunohistochemistry and FISH and analyzed MIP microarray results for correlation with standard tests and survival outcomes. Global genome-wide CNA ranged from 0.2% to 65.7%. Chromothripsis-like patterns were observed in 23/38 (61%) cases and were more prevalent in cases with =10% CNA (20/26, 77%) than in cases with <10% CNA (3/12, 25%; p<0.01). Most frequently involved chromosomal segment was 17q12-q21, the HER2 locus. Chromothripsis-like patterns involving 17q12 were observed in 8/19 (42%) of HER2-amplified tumors but not in any of the tumors without HER2 amplification (0/19; p<0.01). HER2 amplification detected by MIP microarray was 95% concordant with conventional testing (39/41). Interestingly, 21% of patients (9/42) had fibroblast growth factor receptor 1 (FGFR1)amplification and had a 460% higher risk for mortality than those without FGFR1 amplification (p<0.01). In summary, MIP microarray provided a robust assessment of genomic CNA of breast cancer.

[1]  P. Campbell,et al.  Genomic Characterization of Primary Invasive Lobular Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Routbort,et al.  Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array. , 2016, The Journal of molecular diagnostics : JMD.

[3]  L. Varanasi,et al.  Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort , 2016, Genes, chromosomes & cancer.

[4]  Jeffrey H. Chuang,et al.  The tandem duplicator phenotype as a distinct genomic configuration in cancer , 2016, Proceedings of the National Academy of Sciences.

[5]  A. Bousamra.  Molecular Inversion Probe Technology Generates High-Quality HER2 Copy Number Data in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissue , 2016 .

[6]  G. Tse,et al.  FGFR1 is an adverse outcome indicator for luminal A breast cancers , 2015, Oncotarget.

[7]  Cheng-Zhong Zhang,et al.  Chromothripsis: A New Mechanism for Rapid Karyotype Evolution. , 2015, Annual review of genetics.

[8]  L. Saal,et al.  Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing , 2015, Oncotarget.

[9]  Razelle Kurzrock,et al.  The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing , 2015, Clinical Cancer Research.

[10]  Sarah H. Johnson,et al.  Chromosomal catastrophe is a frequent event in clinically insignificant prostate cancer , 2015, Oncotarget.

[11]  Donavan T. Cheng,et al.  Consistent copy number changes and recurrent PRKAR1A mutations distinguish Melanotic Schwannomas from Melanomas: SNP‐array and next generation sequencing analysis , 2015, Genes, chromosomes & cancer.

[12]  P. Tan,et al.  Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer , 2015, Breast Cancer Research and Treatment.

[13]  Phil Quirke,et al.  Cross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling , 2015, BMC Medical Genomics.

[14]  M. Raffeld,et al.  Chromothriptic Cure of WHIM Syndrome , 2015, Cell.

[15]  Jong-Hyeon Jeong,et al.  Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Aldape,et al.  Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours , 2014, British Journal of Cancer.

[17]  G. Babiera,et al.  Molecular cytogenetic characterization of mammary neuroendocrine carcinoma. , 2014, Human pathology.

[18]  C. Greenwood,et al.  Chromosome-breakage genomic instability and chromothripsis in breast cancer , 2014, BMC Genomics.

[19]  J. Baselga,et al.  Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. , 2014, The Lancet. Oncology.

[20]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[21]  Jan Koster,et al.  Prevalence and clinical implications of chromothripsis in cancer genomes , 2014, Current opinion in oncology.

[22]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[23]  Li Ding,et al.  Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. , 2013, Cell reports.

[24]  Rashmi Kanagal-Shamanna,et al.  Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. , 2013, The Journal of molecular diagnostics : JMD.

[25]  J. Korbel,et al.  Criteria for Inference of Chromothripsis in Cancer Genomes , 2013, Cell.

[26]  Mark D. Johnson,et al.  Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes , 2013, Genome research.

[27]  D. Zwijnenburg,et al.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes , 2012, Nature.

[28]  L. Goldstein,et al.  Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  N. Carter,et al.  Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.

[30]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Børresen-Dale,et al.  COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES , 2009, Nature.

[32]  A. Ashworth,et al.  Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis , 2009, The Journal of pathology.

[33]  S. Gunn,et al.  Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event , 2009, Modern Pathology.

[34]  P. Spellman,et al.  High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays , 2009, BMC Medical Genomics.

[35]  S. Tavaré,et al.  High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer , 2007, Genome Biology.

[36]  Des Powe,et al.  FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis , 2007, Breast Cancer Research.

[37]  Kenny Q. Ye,et al.  Novel patterns of genome rearrangement and their association with survival in breast cancer. , 2006, Genome research.

[38]  D. Berry,et al.  Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[40]  C. Osborne,et al.  Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[42]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  D. Birnbaum,et al.  Expression of the FGFR1 gene in human breast‐carcinoma cells , 1994, International journal of cancer.

[44]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.